Deciphering tumor-infiltrating dendritic cells in the single-cell era

Table 2 Clinical relevance of tumor-infiltrating DCs

Cell type	Cancer type	Clinical relevance
cDC1	LUAD	Contribution to anti-tumor immunity [76]
	TNBC	Positively associated with a favorable response to anti-PD-L1 therapy [35]
	Melanoma	Associated with improved clinical outcomes [77]
cDC2	Colorectal liver metastases	High proportion associated with poor prognosis [37]
pDC	NPC	Positively associated a favorable prognosis [45]
LAMP3⁺ DC	CRC	Early activation of primary myeloid cell type with anti-CD40 antibody treatment and association with overall survival [38]
	NSCLC	Positively associated with clinical response to neoadjuvant pembrolizumab and chemotherapy [44]
	CRC	Increased frequency after anti-CD40 antibody treatment and associated with favorable overall survival [41]
moDC	Melanoma	Upregulation of inducible iNOS, promotion of T-cell expansion, and anti-tumor immunity following combination treatment with anti-PD1 and anti-CD40 targeting moDCs [89]

cDC conventional DC, pDC plasmacytoid DC, moDC monocyte-derived DC, LUAD lung adenocarcinoma, TNBC triple-negative breast cancer, NSCLC non-small cell lung cancer, NPC nasopharyngeal carcinoma, CRC colorectal cancer, iNOS inducible nitric oxide synthase

ISSN: 2162-3619